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Ibogaine is an indole alkaloid originally extracted from the root bark of the African rainforest shrub Tabernanthe iboga. It has been
explored as a treatment for substance abuse because it interrupts drug addiction and relieves withdrawal symptoms. However, it has
been shown that ibogaine treatment leads to a sharp and transient fall in cellular ATP level followed by an increase of cellular
respiration and ROS production. Since contractile tissues are sensitive to changes in the levels of ATP and ROS, here we
investigated an ibogaine-mediated link between altered redox homeostasis and uterine contractile activity. We found that low
concentrations of ibogaine stimulated contractile activity in spontaneously active uteri, but incremental increase of doses
inhibited it. Inhibitory concentrations of ibogaine led to decreased SOD1 and elevated GSH-Px activity, but doses that
completely inhibited contractions increased CAT activity. Western blot analyses showed that changes in enzyme activities were
not due to elevated enzyme protein concentrations but posttranslational modiﬁcations. Changes in antioxidant enzyme activities
point to a vast concentration-dependent increase in H2O2 level. Knowing that extracellular ATP stimulates isolated uterus
contractility, while H2O2 has an inhibitory eﬀect, this concentration-dependent stimulation/inhibition could be linked to
ibogaine-related alterations in ATP level and redox homeostasis.
1. Introduction
Ibogaine is a psychoactive indole alkaloid derived from
the rainforest shrub Tabernanthe iboga, which grows in
West Africa. The tribes of Gabon have used the iboga
plant root bark as a stimulant, for medicinal purposes,
and in rite of passage ceremonies, for centuries. The
pharmacological properties of ibogaine have been known
for over 100 years. During the early period of exploration,
ibogaine was mostly known for its ability to inspire a
sense of wellbeing both mentally and physically. Ibogaine
has also been used for the treatment of substance abuse
because it interrupts drug addiction, relieves withdrawal
symptoms, and signiﬁcantly decreases the desire for
cocaine, heroin, alcohol, and most other mind-altering
drugs [1–4]. The pharmacology of ibogaine is quite com-
plex and aﬀects many diﬀerent neurotransmitter systems
simultaneously. Ibogaine binds to several types of recep-
tors: 5-hydroxytryptamine (5-HT), opioid, nicotinic, and
N-methyl-D-aspartate (NMDA), as well as dopaminergic
and 5-HT transporters and monoamine oxidase (MAO)
enzyme [5–7].
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Paskulin et al. have shown that ibogaine causes a
sharp and transient fall in the cellular ATP level in yeast,
which was followed by an immediate increase in respira-
tion and CO2 production, in a time- and concentration-
dependent manner [8, 9]. Increased respiration leads to
an increase in ROS production, changes in cellular redox
state, and subsequent activation of antioxidant enzymes.
These eﬀects of ibogaine are not mediated by receptor
binding [8, 10]. The proteome changes (induction of energy
metabolism enzymes, antioxidant enzymes, and numerous
low-abundance proteins) are responsible for at least a
part of the initial energy expenditure in ibogaine-treated
yeast [8, 11]. A study on human blood erythrocytes also
showed that ibogaine leads to the release of ATP and
the elevation of antioxidant activity [10]. Ibogaine does
not have any signiﬁcant in vitro antioxidant properties
per se, so its inﬂuence on the physiological oxidative stress
defense system has been suggested to be in a proantioxidant
manner [9, 10].
Contractile tissues are sensitive to ATP levels, and the
depletion of energetics could lead to the impairment of regu-
lar rhythms and reversible inhibition of contractile activity
[12]. Extracellular ATP is known to stimulate uterine
contractions in diﬀerent species, but the exact underlying
mechanisms are poorly investigated [13]. Furthermore, dif-
ferent contractile tissues, including uterus, are also sensitive
to changes of the cellular redox state and ROS [14], especially
hydrogen peroxide (H2O2) [15, 16]. Moreover, the antioxi-
dant enzyme cytosolic copper-zinc-containing superoxide
dismutase (SOD1) can also aﬀect the contractility of uterine
smooth muscles [17]. These points out that cellular energetic
consumption, subsequent redox modiﬁcations, and antioxi-
dant defense make an intracellular net that inﬂuences
smooth muscle contractility.
Keeping in mind the eﬀects of ibogaine on cellular
energy and ROS metabolism, the aim of this study was to
investigate the eﬀects of ibogaine on the activity and
expression of antioxidant enzymes in isolated rat uteri
and a possible link between ibogaine-altered redox homeo-
stasis, antioxidant defense, and the contractile properties of
the uterus. To that end, we studied the eﬀect of increasing
concentrations of ibogaine (1, 2, 5, 10, 15, 20, 40, and
60mg/l) on an isolated rat uterus in conditions of low
(spontaneous) and high (Ca2+-stimulated) intensity of con-
tractions, as well as the expression and activity of antioxi-
dant enzymes: cytosolic copper-zinc-containing superoxide
dismutase (SOD1), mitochondrial manganese-containing
superoxide dismutase (SOD2), catalase (CAT), glutathione
peroxidase (GSH-Px), and glutathione reductase (GR).
2. Materials and Methods
2.1. Materials. The ibogaine hydrochloride employed in the
study came from two sources: one source (PubChem CID:
197059), purity 98.93%, was donated by Sacrament of Tran-
sition, Maribor, Slovenia. The other source was Remøgen
(Phytostan Enterprises Inc., Canada), 99.9% pure ibogaine
HCl, provided by MB and PI of the LNPR project under
ARRS Programme P3-0171.
2.2. Animals. The procedures complied with the EEC Direc-
tive on the protection of animals used for experimental and
other scientiﬁc purposes and were approved by the Ethical
Committee for the Use of Laboratory Animals of the Institute
for the Biological Research “Siniša Stanković,” University of
Belgrade. Animals were kept at 22°C, housed 3 per cage,
and fed ad libitum. Experiments were performed on isolated
uteri from female virgin Wistar rats three months old (200–
250 g) in the estrus phase of the estrous cycle, which was
determined by examination of a daily vaginal lavage [18].
2.3. Isolated Organ Bath Studies. All rats were sacriﬁced by
rapid decapitation. The uterine horns were rapidly excised
and carefully cleaned of surrounding connective tissues and
mounted vertically in a 10ml volume organ bath containing
De Jalon’s solution (in g/l: NaCl 9.0, KCl 0.42, NaHCO3 0.5,
CaCl2 0.06, and glucose 0.5), under initial tension of 1 g,
aerated with a mixture of 95% oxygen and 5% carbon dioxide
at 37°C. After an equilibration period (about 30min), uteri
achieved stable spontaneous contractions (this activity is
referred to as spontaneous contractions). Another set of uteri
was additionally activated by the addition of 0.66 g/l of CaCl2
in an organ bath (referred to as Ca2+-stimulated contrac-
tions) to achieve maximal intensity of phasic contractions.
The eﬀect of ibogaine on uterine contractility was studied
by cumulative ibogaine addition up to complete contractility
inhibition (concentrations: 1, 2, 5, 10, 15, 20, and 40mg/l for
spontaneously active uteri and 1, 2, 5, 10, 15, 20, 40, and
60mg/l for Ca2+-stimulated uteri). Myometrial tension was
recorded isometrically with a TSZ-04-E isolated organ bath
and transducer (MDE Research, Heidelberg, Germany). To
determine if ibogaine eﬀects were reversible, uteri were
washed out after treatment by De Jalon’s solution. For corre-
sponding controls, both untreated spontaneously active
and Ca2+-stimulated uteri placed in an isolated organ bath
parallel to treated samples were used.
In order to determine the eﬀect of ibogaine inhibitory
concentrations on antioxidant enzyme activities in uteri, an
additional group of both spontaneously active and Ca2+-
stimulated active uteri were treated with increasing concen-
trations of ibogaine up to 20mg/l, which was shown as the
cumulative dose that inhibited uterine contractions up to
about 50% of controls.
After the described treatments, samples were immedi-
ately frozen using liquid nitrogen and transferred to −80°C
until further analysis.
2.4. Determination of Antioxidant Enzyme Activities. Thawed
uteri were homogenized and sonicated in 0.25M sucrose,
1mM ethylenediaminetetraacetic acid, and 0.05M Tris-
HCl buﬀer (pH7.4) before centrifugation for 90min at
105,000×g. The supernatant was used to determine enzyme
activities. Total superoxide dismutase (SOD) activity was
determined by the adrenaline method [19]. One SOD unit
was deﬁned as the amount of the enzyme necessary to
decrease the rate of adrenalin auto-oxidation by 50% at
pH10.2. For determination of SOD2 activity, the assay was
performed after preincubation with 8mM KCN. The SOD1
activity was calculated as the diﬀerence between the total
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SOD and SOD2 activities. CAT activity was determined by
the monitoring of hydrogen peroxide consumption [20]
and expressed in U/mg protein. The activity of GSH-Px
was determined using t-butyl hydroperoxide as a substrate
[21] and expressed in mU/mg protein. GR activity was
determined by NADPH oxidation concomitant with GSSG
reduction [22] and expressed in mU/mg protein. Protein
concentration was measured by the method of Lowry
et al. [23]. All measurements of absorbance were per-
formed using a Shimadzu UV-160 spectrophotometer
(Shimadzu Scientiﬁc Instruments, Shimadzu Corporation,
Kyoto, Japan).
2.5. SDS-PAGE and Immunoblotting. Whole cell extracts
from control and treated uteri were mixed 1 : 1 with Laemmli
sample buﬀer, boiled for 5min, and stored at −80°C until
further analysis. Proteins were resolved in 12% SDS poly-
acrylamide gels and transferred to PVDF membranes.
SOD1, SOD2, CAT, GSH-Px, and GR were detected by
Abcam antibodies (ab13498, ab13533, ab16731, ab22604,
and ab16801, resp.). β-Actin was detected by AC-15 anti-
body (Sigma-Aldrich). After incubation with secondary
antibodies, the immunoreactive proteins were visualized by
the enhanced chemiﬂuorescence (ECF) method (Amersham
Biosciences Limited, UK). Quantitative analysis of immu-
noreactive bands was performed using the ImageQuant
software. β-Actin was used as equal load control.
2.6. Data Analysis and Statistical Procedures. Statistical
analyses were performed according to the protocols
described by Hinkle et al. [24]. The eﬀects of treatments
on uterine contractions were calculated as percentages of
control. Contractions were analyzed for the force of
contraction, amplitude, and frequency. Each data value
is expressed as mean± SEM. The forces of contractions
of spontaneously active uteri and Ca2+-stimulated uteri
during the control period was compared using a t-test
(signiﬁcance: p < 0 05). The eﬀect of ibogaine on uterine
contractility was tested by two-way ANOVA (factors:
type of contractions and concentration of ibogaine) on
logarithmically transformed data and post hoc compared
by Tukey’s HSD test (signiﬁcance: p < 0 05). Sigmoid
concentration-response curves for ibogaine treatment were
ﬁtted according to Boltzmann functions (the concentration
axis was linear), and the concentration required for the
half-maximal eﬀect (EC50) was calculated. Fitted curves
were compared using an F-test. EC50 values were com-
pared using the t-test (signiﬁcance: p < 0 05). The activities
and protein expression levels of antioxidant enzymes were
compared by one-way ANOVA followed by Tukey’s HSD
post hoc test (signiﬁcance: p < 0 05). Diﬀerences in the
activity of antioxidant enzymes in spontaneously active
versus Ca2+-stimulated uteri were compared using the t-test
(signiﬁcance: p < 0 05).
3. Results
3.1. Eﬀects of Increasing Concentrations of Ibogaine on
Uterine Contractions. Ibogaine in concentrations applied
in our experiment signiﬁcantly inﬂuenced the contractile
activity of uterus in a dose-dependent manner, but eﬀects
on spontaneously active and Ca2+-stimulated active rat uteri
were diﬀerent and depended on the applied concentration
(Figures 1 and 2; ANOVA eﬀects of both concentration,
p < 0 001, and interactions, p < 0 001). In spontaneously
active uteri, low concentrations increased the force of con-
traction and frequency, while higher concentrations caused
a dose-dependent decrease in complete contractile activity
(Figures 1 and 2; signiﬁcant ANOVA concentration eﬀect
and sigmoidal ﬁt for the observed data). Cumulative
concentrations of 40mg/l led to the complete inhibition of
the contractile activity of the spontaneously active rat uterus
(Figures 1(a) and 2). On the other hand, ibogaine had no
stimulating eﬀect on the force of contraction in Ca2+-stimu-
lated uteri, although a small increase (but statistically not
signiﬁcant) in amplitude and frequency is noted at low con-
centrations (Figures 1(b) and 2). Higher concentrations of
ibogaine caused a dose-dependent decrease in contractile
activity. A cumulative concentration of 60mg/l has led
to an almost complete inhibition of contractile activity
(Figures 1(b) and 2). The force of contractions of Ca2+-
stimulated uteri was about 5 times greater than that in spon-
taneously active uteri (Figure 1(c)), and the concentration of
ibogaine eﬀective for the inhibition of spontaneously active
uteri is lower than that for Ca2+-stimulated uteri (signiﬁcant
diﬀerence ANOVA for type of contraction eﬀect for all three
calculated parameters, as well as for calculated EC50 concen-
trations (t-test, p < 0 001) and curve shape for amplitude
obtained by the F-test (p < 0 001), Figure 2).
The cease of contractility was reversible in both sponta-
neously active and Ca2+-stimulated rat uteri, since washing
out of isolated ibogaine-treated uteri restored their contrac-
tile activity (Figures 1(a) and 1(b)).
3.2. Eﬀects of Increasing Concentrations of Ibogaine on the
Activity of Antioxidant Enzymes. In nontreated active control
Ca2+-stimulated uteri, SOD1, SOD2, and CAT activities were
30%, 2-fold, and 2.4-fold higher, respectively, compared to
spontaneously active uteri for the same period of contractile
activity (Figure 3(a)). At the same time, GSH-Px and GR
activities were at the same level.
In both spontaneously active and Ca2+-stimulated active
uteri, cumulative concentrations of ibogaine up to 20mg/l
(which caused an inhibition of about 50% of contractile
activity) decreased the SOD1 activity and increased the
GSH-Px activity compared to corresponding controls
(Figures 3(b) and 3(c)). Further addition of ibogaine up to a
total cease in contractile activity (40mg/l and 60mg/l for
spontaneously active and Ca2+-stimulated active uteri, resp.)
led to a further decrease in SOD1 activity to less than 20% of
its initial activity, a multiple increase in CAT activity (a 30-
fold and a 13-fold increase compared to the control in spon-
taneously active and Ca2+-stimulated active uteri, resp.), and
a fall in previously elevated GSH-Px (Figures 3(b) and 3(c)).
The levels of CAT activity after ibogaine treatment up to the
inhibition of contractile activity were about the same in
both spontaneously active and Ca2+-stimulated active uteri
(Figure 3(d)). Besides, ibogaine treatment of Ca2+-stimulated
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uteri decreased the SOD2 activity at both experimental
points of 20mg/l and 60mg/l. There were no signiﬁcant
changes in SOD2 activity in spontaneously active uteri
during ibogaine treatment.
3.3. Eﬀects of Increasing Concentrations of Ibogaine on the
Protein Expression Levels of Antioxidant Enzymes. The pro-
tein expression levels of antioxidant enzymes in response to
ibogaine treatment remained unaltered (Figure 4). Both
spontaneously active and Ca2+-stimulated uteri, at both
experimental points (20mg/l and 40mg/l for spontaneously
active and 20mg/l and 60mg/l of ibogaine for Ca2+-
stimulated uteri), showed no signiﬁcant changes comparing
to controls.
4. Discussion
Despite its pharmacological properties, it was shown that
ibogaine disturbed the redox homeostasis: it provoked ATP
depletion and subsequent resynthesis followed by high ROS
generation. ATP depletion is rapid after ibogaine addition,
and elevated ROS concentration persisted during the
following hours [8, 9]. Since it was shown that contractile
activity is associated with changes in ROS homeostasis and
antioxidant defense, here we studied the physiological
response on the level of antioxidant activity to ibogaine
application and possible link to uterine contractility.
Our results showed that ibogaine cumulative treatment
led to changes in uterine antioxidant activity in parallel to
the inhibition of contractile activity. The eﬀects are diﬀerent
for spontaneously active and Ca2+-stimulated uteri. Low
doses of ibogaine signiﬁcantly elevated the frequency and
contractile activity of already spontaneously active uteri. This
eﬀect could be partly attributed to a possible increase in the
extracellular concentration of ATP. This assumption is based
on the fact that ibogaine liberates ATP from the cellular ATP
pool. Our previous results showed that ibogaine releases ATP
from human erythrocytes [10]. It is also known that ATP,
under the inﬂuence of various stimuli, can be released from
various cell types through speciﬁc transport mechanisms
[25, 26] and that addition of extracellular ATP stimulates
the contractile activity of the isolated uterus [13]. On the
other hand, stimulation of uterine activity by Ca2+ led to a
signiﬁcant increase in contractility, to the point that elevation
of ATP by ibogaine addition seems insuﬃcient to change the
contractility for that type of contraction.
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Figure 1: The eﬀects of increasing concentrations of ibogaine on uterine contractions. (a) Representative original trace of spontaneously
active uterus treated with increasing concentrations of ibogaine (1–40mg/l); W=washing out. (b) Representative original trace of
Ca2+-stimulated uterus treated with increasing concentrations of ibogaine (1–60mg/l). (c) Force of contractions of spontaneously
active and Ca2+-stimulated active uteri during the control period, before the addition of ibogaine, calculated as area under the curve
per minute. Values are means± SEM (n = 7) and presented as percentage of Ca2+-stimulated contractions. Diﬀerence was tested by the
t-test. ∗∗∗p < 0 001.
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Figure 2: Continued.
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Given that ATP (re)synthesis entails an immediate ele-
vation of ROS, we measured the activity of antioxidant
enzymes in uteri at two experimental points: at cumulative
concentrations of ibogaine that inhibited uterine contrac-
tions up to about 50% of controls (20mg/l of ibogaine for
both types of contractions) and at the end of treatment after
inhibition of contractility was obtained (40mg/l of ibogaine
for spontaneously active and 60mg/l for Ca2+-stimulated
uteri). In both types of contractile activity, the concentration
of 20mg/l of ibogaine caused an elevation in GSH-Px activity
and a decrease in SOD1 activity. On the other hand, the con-
centration of ibogaine that caused an inhibition of contractile
activity led to a 30-fold increase in CAT activity, while SOD1
activity was still decreased. Since the substrate for both GSH-
Px and CAT is H2O2, results indicate high level of hydrogen
peroxide after ibogaine addition. Since CAT operates at
higher concentration of H2O2 than GSH-Px, it seems that
the production of H2O2 was higher at higher concentrations
of the applied ibogaine. Furthermore, ibogaine decreased the
cytosol SOD1 activity in active uteri in a concentration-
dependent manner, down to 20% of the initial activity. This
further points to the presence of high concentrations of
H2O2 and a gradual increase in H2O2 in the uterus, since it
is known that H2O2, as a product of SOD, can inhibit its
activity by a negative feedback eﬀect [27].
Our previous results [15, 16] showed that H2O2 can
induce concentration-dependent contractile inhibition of
isolated rat uteri, mainly via changes in voltage-dependent
potassium channels. According to these results, high
ibogaine concentration-mediated inhibition of contraction
found in the present study may be attributable to the inﬂu-
ence of H2O2 on contractile activity. Inhibition of uterine
contractility is transient and reversible: washing ibogaine
out of the isolated uterus restores contractile activity, which
emphasizes the role of receptor-mediated mechanisms in
ibogaine action. Therefore, the role of hydrogen peroxide
can be considered as mediatory. However, some other
possible mechanisms of ibogaine-induced smooth muscle
inhibition of contractility cannot be eliminated, considering
its wide range of interaction with diﬀerent receptors and
signal transduction pathways.
An increase in the intensity of smooth muscle contrac-
tions induces elevated oxidative metabolism and leads to an
increased production of ROS in the system [28]. To investi-
gate whether this is a mechanism by which ibogaine operates
at the level of antioxidant activity in spontaneously active
uteri or it is the consequence of the direct impact on the
energy metabolism, we used Ca2+-stimulated uteri. Placing
uteri in isotonic solution containing 11-fold higher concen-
trations of Ca2+, we stimulated the inﬂux of Ca2+ in uterine
muscles and induced a high elevation of contractile activity.
In these conditions, uterine contractions as well as energy
demands are very intensive (force of contractions 5 times
greater compared to spontaneous activity). However, in these
conditions, ibogaine showed no initial stimulating eﬀect and
caused a further concentration-dependent inhibition of
Ca2+-stimulated uterine contractions. We found that these
conditions stimulate the antioxidant activity by increasing
0 10 20 30 40 50 60
0
100
200
300
F-test
Concentration of ibogaine (mg/l)
Fr
eq
ue
nc
y 
(%
 o
f c
on
tro
l)
Two way ANOVA
Type F = 13.7
Concentration F = 10.9 p < 0.001
p < 0.001
p < 0.001Interaction F = 4.9
sp EC50 = 15.0 ± 2.4
Ca EC50 = 21.0 ± 1.9
t-test NS
NS
sp
Ca
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
(c)
Figure 2: Concentration-response sigmoid ﬁt curves for ibogaine-treated uteri: (a) force of contractions, (b) amplitude, and (c) frequency.
Force of contractions, amplitudes, and frequencies were calculated as percentage of controls and expressed as mean values± SEM (n = 7).
Diﬀerences were tested by two-way ANOVA (factors: type of contraction and concentration of ibogaine). The sigmoid ﬁts were performed
according to the Boltzmann equation (ﬁts were compared by the F-test) and EC50 values were expressed. Diﬀerences between EC50 values
were tested by the t-test. ∗∗p < 0 01, ∗∗∗p < 0 001.
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SOD1, SOD2, and CAT activities (30%, 2-fold, and 2.4-fold
higher, resp., compared to spontaneous activity) in a similar
direction as measured in spontaneously active uteri (the
elevation of GSH-Px activity in lower doses and the increase
in CAT activity up to the same level as the maximal concen-
tration of ibogaine applied to spontaneously active uteri).
These suggest that the metabolic eﬀects of ibogaine at ROS
and antioxidant enzyme levels are similar in both types of
uterine activity, but diﬀerent in intensity. In Ca2+-stimulated
uteri, the inhibition of mitochondrial SOD2 activity was also
shown. Since mitochondrial SOD2 activity can be also
inhibited by H2O2 [29, 30], a parallel inhibition of both
SOD1 and SOD2 in Ca2+-stimulated uteri suggests a higher
rate of H2O2. Moreover, levels of CAT after ibogaine treat-
ment reached the same level in both types of uterine activity,
suggesting that the existing amount of CAT has reached its
highest rate of activity. A large increase in the ATP turnover
rate, which is reﬂected by a concentration-dependent
increase in H2O2 in the system, could only partially be related
to increased energy demands caused by stronger contractile
activity. Even when the uterus is contracting with maximal
intensity in our experiment, the addition of ibogaine leads
to additional multiple increases in CAT activity and a
decrease in SOD activity, indicating the existence of other
ways of ROS/redox disequilibrium induced by ibogaine.
Since there were no changes in the protein levels of any
studied antioxidant enzyme (unaltered protein expression)
in our experiment, stimulatory/inhibitory changes of its
activities found in this work were based on the regulation
of existing quantities of enzymes and can be attributed to
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Figure 3: The activity of antioxidant enzymes in the uterus after treatment with increasing concentrations of ibogaine. (a) The activity of
antioxidant enzymes in spontaneously active and Ca2+-stimulated active uteri. (b) Spontaneously active uteri treated with increasing
concentrations of ibogaine (up to 20 and 40mg/l). (c) Ca2+-stimulated active uteri treated with increasing concentrations of ibogaine
(up to 20 and 60mg/l). (d) The activity of CAT in both spontaneously active and Ca2+-stimulated active uteri. Data are expressed as
mean± SEM (n = 7). For (a) and (d), statistical signiﬁcance was tested using the t-test. For (b) and (c), statistical signiﬁcance was
tested by one-way ANOVA and post hoc compared by Tukey’s HSD test. ∗∗∗p < 0 001, ∗∗p < 0 01, and ∗p < 0 05.
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the intrinsic characteristics of enzymes and/or posttransla-
tional modiﬁcation(s). It was already shown that SOD can
be inhibited by its own product—H2O2 [27, 29, 30]. On the
other hand, increasing levels of H2O2 lead to GSH-Px and
CAT activation by phosphorylation by the tyrosine kinase
c-Abl/Arg complex by diﬀerent kinetics [31, 32]. Moreover,
CAT activity is under control of diﬀerent phosphatases
[33]; its inhibitory eﬀects are suppressed by the excess of
calcium [34]. Furthermore, it was shown that external Ca2+
addition induced signiﬁcantly the generation of ROS and
Ca2+ inﬂux [34]; this can be one of the reasons way CAT
initial activity levels are higher in Ca2+-stimulated uteri
compared to spontaneously active uteri. However, the
addition of ibogaine further deepened the state of oxidative
stress, suggesting ibogaine-mediated oxidative input that
led to a physiological response toward the establishment of
ROS homeostasis.
5. Conclusions
Overall, in our experimental setting, ibogaine treatment
altered the redox homeostasis and aﬀected the contractile
properties of the uterus. Changes in antioxidant enzyme
activities point to a vast, concentration-dependent increase
in cellular respiration and H2O2 level. The results show
that ibogaine aﬀects both spontaneously active and Ca2+-
stimulated contractions. Low concentrations of ibogaine
stimulated spontaneous contractions, which might be, at
least in part, related to an increase in extracellular ATP.
On the other hand, high ibogaine concentrations exhibited
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Figure 4: Protein levels of antioxidant enzymes in the uterus after treatment with increasing concentrations of ibogaine. (a) Protein levels of
antioxidant enzymes in spontaneously active uteri (representativeWestern blots are shown underneath the corresponding charts). (b) Protein
levels of antioxidant enzymes in Ca2+-stimulated uteri (representative Western blots are shown underneath the corresponding charts). Whole
cell extracts from uteri (50 μg protein) were subjected to SDS-PAGE and Western blotting. β-Actin was used as loading control.
Representative Western blots and relative quantiﬁcation of antioxidant enzyme levels of control uteri (C). Uteri treated with increasing
concentrations of ibogaine up to both 20mg/l and 40mg/l are shown. Values are means± SEM (n = 6) and are presented as percentage
of control.
8 Oxidative Medicine and Cellular Longevity
inhibiting eﬀects on both spontaneously active and Ca2+-
stimulated active uteri. This decrease in the contractile
activity of isolated uteri is at least partially contributed
by ibogaine-related alterations in redox homeostasis and
changes in ROS equilibrium.
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